home / stock / acet / acet quote
Last: | $1.51 |
---|---|
Change Percent: | -0.65% |
Open: | $1.56 |
Close: | $1.51 |
High: | $1.61 |
Low: | $1.46 |
Volume: | 863,732 |
Last Trade Date Time: | 07/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.51 | $1.56 | $1.51 | $1.61 | $1.46 | 863,732 | 07-31-2024 |
$1.55 | $1.61 | $1.55 | $1.63 | $1.51 | 847,443 | 07-30-2024 |
$1.63 | $1.61 | $1.63 | $1.7 | $1.58 | 1,146,407 | 07-29-2024 |
$1.59 | $1.52 | $1.59 | $1.63 | $1.4 | 1,008,262 | 07-26-2024 |
$1.51 | $1.44 | $1.51 | $1.5189 | $1.43 | 527,799 | 07-25-2024 |
$1.45 | $1.39 | $1.45 | $1.5 | $1.39 | 759,426 | 07-24-2024 |
$1.44 | $1.37 | $1.44 | $1.45 | $1.335 | 990,307 | 07-23-2024 |
$1.37 | $1.24 | $1.37 | $1.3799 | $1.22 | 1,634,538 | 07-22-2024 |
$1.24 | $1.26 | $1.24 | $1.26 | $1.16 | 1,226,251 | 07-19-2024 |
$1.23 | $1.32 | $1.23 | $1.32 | $1.22 | 983,497 | 07-18-2024 |
$1.31 | $1.28 | $1.31 | $1.35 | $1.25 | 1,392,262 | 07-17-2024 |
$1.28 | $1.25 | $1.28 | $1.305 | $1.21 | 3,149,104 | 07-16-2024 |
$1.23 | $1.22 | $1.23 | $1.28 | $1.18 | 949,961 | 07-15-2024 |
$1.21 | $1.26 | $1.21 | $1.27 | $1.2 | 1,117,667 | 07-12-2024 |
$1.26 | $1.26 | $1.26 | $1.28 | $1.22 | 975,435 | 07-11-2024 |
$1.27 | $1.22 | $1.27 | $1.3 | $1.205 | 1,240,215 | 07-10-2024 |
$1.21 | $1.18 | $1.21 | $1.23 | $1.17 | 1,140,748 | 07-09-2024 |
$1.17 | $1.2 | $1.17 | $1.2 | $1.15 | 1,969,604 | 07-08-2024 |
$1.07 | $1.1 | $1.07 | $1.13 | $1.07 | 721,545 | 07-05-2024 |
$1.09 | $1.1 | $1.09 | $1.12 | $1.05 | 830,888 | 07-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferi...